Visceral Leishmaniasis Due to a Leishmania Variant That Shares Kinetoplast DNA Sequences with Leishmania braziliensis and Leishmania mexicana in a Patient Infected with Human Immunodeficiency Virus: Identification of the Leishmania Species with Use of the Polymerase Chain Reaction

1995 ◽  
Vol 21 (3) ◽  
pp. 701-702 ◽  
Author(s):  
D. E. Hernandez ◽  
N. Rodriguez ◽  
M. Wessolossky ◽  
J. Convit
Keyword(s):  
Human Immunodeficiency Virus ◽  
Dna Sequences ◽  
Leishmania Species ◽  
Leishmania Braziliensis ◽  
Kinetoplast Dna ◽  
Leishmania Mexicana ◽  
Chain Reaction ◽  
Virus Identification ◽  
Immunodeficiency Virus ◽  
Polymerase Chain

Identification and diagnosis of Leishmania mexicana complex isolates by polymerase chain reaction

Parasitology ◽  
1994 ◽  
Vol 109 (4) ◽  
pp. 423-433 ◽  
Author(s):  
S. Eresh ◽  
S. M. McCallum ◽  
D. C. Barker
Keyword(s):  
Polymerase Chain Reaction ◽  
Dna Sequences ◽  
The Other ◽  
South American ◽  
Kinetoplast Dna ◽  
Leishmania Mexicana ◽  
Chain Reaction ◽  
Potential Host ◽  
Oligonucleotide Primers ◽  
Polymerase Chain

SUMMARYFollowing cloning of Leishmania (L.) amazonensis kinetoplast DNA two recombinant clones were identified: one specific for L. (L.) amazonensis and the other specific for L. (L.) amazonensis and closely related isolates. DNA sequences from these clones were compared with those of other kinetoplastids and oligonucleotide primers were designed to be used in the polymerase chain reaction. A pair of these primers has been shown not only to be highly specific for L. mexicana complex isolates but can also be used to distinguish between L. (L.) mexicana and L. (L.) amazonensis isolates. These primers have been tested with water-lysed cultures, crude DNA extracts from human patients, potential host reservoirs, sandfly vectors and with cell pellets after isoenzyme characterization. The results of these tests indicate that the primers can be used specifically in the presence of excess host DNA originating from the majority of South American countries.

scholarly journals Introduction of NAT-testing for infections for screening blood donors in Republic of Kazakhstan

2015 ◽  
Vol 96 (3) ◽  
pp. 414-417
Author(s):  
T N Savchuk ◽  
Z K Burkitbaev ◽  
S A Abdrakhmanova ◽  
S V Skorikova ◽  
N S Kuz’min
Keyword(s):  
Human Immunodeficiency Virus ◽  
Polymerase Chain Reaction ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Blood Donors ◽  
Chain Reaction ◽  
B Virus ◽  
Immunodeficiency Virus ◽  
Polymerase Chain

Aim. To evaluate the effectiveness of NAT-screening (nucleic acid amplification technologies) for infections in blood donors in Kazakhstan. Methods. Statistical data of blood donors screening examinations in the Republic of Kazakhstan in 2012-2014 were evaluated. Results. In 2014, the number of examined donors increased by 3.4% compared with 2012. The number of deferrals due to positive screening results for serological markers decreased by 10.9%, while the share of such donors decreased by 13.8% [p <0.01; odds ratio (OR) - 0.86, 95% confidence interval (CI 95%) - 0.83-0.88); χ2=136.76]. In 2014, 100% of donations were screened using NAT-testing (312,510 donors). Most of the NAT-screening in Kazakhstan is performed using closed automated systems. In 2012, 1 Blood Center conducted a polymerase chain reaction screening by open circuit polymerase chain reaction systems, in 5 blood centers polymerase chain reaction was performed with manual sample preparation. In 2014, the number of deferrals due to positive NAT-testing results has increased by 44.3%, the share of such donors - by 38.7% (p <0.01; OR=1.39, 95% CI=1.15-1.67); χ2=11.82). Seronegative NAT-positive samples were discovered according to the results of discriminant test, including human immunodeficiency virus - 2 (0.8%) samples, hepatitis B virus -182 (73.4%), hepatitis C virus - 60 (24.2%), negative result - 4 (1.6%). Conclusion. The introduction of screening NAT-testing of donated blood prevented transfusion of blood infected with: human immunodeficiency virus - 1 in 150,000 donations, hepatitis B virus - 1 in 1.650 donations, hepatitis C virus - 1 in 5,000 donations.

Sign in / Sign up

Export Citation Format

Share Document